Search

Abstract. Phosphorilated polyprenols (PP) isolated from different sources are known to exert immunomodulating and antiviral activities. In this paper possible anti-inflammatory action of PP were studied using sensitive models of 5-lypoxigenase and 15-lypoxigenase activity inhibition, as well as a model of the hypostasis induced by the complete Freundt’s adjuvant, or carraginan. Also in vitro model of bronchospasm was used to study prospective broncholytic activity of PP. The latter was found to exert dose-dependent inhibitory effect upon both 5-lypoxigenase and 15-lypoxigenase activity. In the suspension cell culture significant inhibitory effect of PP upon leukotriens production was found even at a concentration of 5 mcg/ml; at concentration of 100 mkg/ml activity of the enzyme was suppressed almost to zero. In neutrophil cells cultivated on a collagenic substrate the significant inhibitory effect was also found at the concentration of 5 mcg/ml; 20 mcg/ml of PP reduced 5-LOX activity approximately 20-fold. In another protocol PP significantly inhibited 15-LOX activity. Thus, PP may be regarded as active inhibitor of both lipoxygenases. The PP exerted anti-inflammatory activity at both models of hypostasis, though it was weaker compared with indomethacin. Also PP was found to possess broncholytic activity in vitro in the bronchospasm model. Taking into account early established findings proving that PP may function as a physiological counterregulator of MIF (macrophage inhibitory factor), a major pro-inflammatory cytokine, our data prove that PP possess anti-inflammatory and broncholytic activities, which might be used for development of novel drugs for preventive care and treatment of bronchial asthma, inflammatory diseases and other pathologies.